“Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neoantigen Based Personalized Cancer Therapeutic Vaccines Market.

The Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Report:

• Companies across the globe are diligently working toward developing novel Neoantigen Based Personalized Cancer Therapeutic Vaccines treatment therapies with a considerable amount of success over the years.

• Neoantigen Based Personalized Cancer Therapeutic Vaccines companies working in the treatment market are Evaxion Biotech, Nouscom, Amgen, Dendreon Pharmaceuticals, IO Biotech, Candel Therapeutics, Merck/Moderna, Geneos Therapeutics, Enterome, Johnson & Johnson, and others, are developing therapies for the Neoantigen Based Personalized Cancer Therapeutic Vaccines treatment

• Emerging Neoantigen Based Personalized Cancer Therapeutic Vaccines therapies in the different phases of clinical trials are- EVX-01, NOUS-PEV, IMLYGIC (talimogene laherparepvec), PROVENGE (sipuleucel-T), IO102-IO103, CAN-2409, mRNA-4157 (V940) + KEYTRUDA, GNOS-PV02, EO2401, VAC85135, and others are expected to have a significant impact on the Neoantigen Based Personalized Cancer Therapeutic Vaccines market in the coming years.

• In December 2024, NEC Bio Therapeutics unveiled promising 24-week interim results from its ongoing Phase 1 basket trial evaluating NECVAX-NEO1, an orally administered cancer vaccine, in combination with checkpoint inhibitors (CPI) for treating solid tumors. NECVAX-NEO1 is a personalized, bacteria-based oral DNA therapeutic vaccine developed using AI-driven prediction of patient-specific neoepitopes. Designed to stimulate the immune system, the vaccine triggers a T-cell response that precisely targets and eliminates tumor cells based on an individual’s unique neoantigens.

• In April 2024, Geneos Therapeutics reported positive Phase I/II results from the GT-30 trial evaluating GNOS-PV02 for advanced hepatocellular carcinoma, with select clinical trial findings also presented at the 2024 AACR Annual Meeting.

• According to the April 2024 presentation, IO Biotech’s Phase III pivotal trial of IO102-IO103 has completed enrollment, with progression-free survival (PFS) as the primary endpoint. An interim analysis is anticipated in Q3 2024, and if the results are favorable, the therapy could receive accelerated approval in 2025.

Neoantigen Based Personalized Cancer Therapeutic Vaccines Overview

Neoantigen-based personalized cancer therapeutic vaccines are a type of immunotherapy designed to stimulate the immune system to recognize and attack cancer cells. These vaccines are tailored to individual patients based on tumor-specific neoantigens, which are unique mutated proteins found in cancer cells but not in normal tissues.

Get a Free Sample PDF Report to know more about Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neoantigen-based-personalized-cancer-therapeutic-vaccines-pipeline-insight

Emerging Neoantigen Based Personalized Cancer Therapeutic Vaccines Drugs Under Different Phases of Clinical Development Include:

• EVX-01: Evaxion Biotech

• NOUS-PEV: Nouscom

• IMLYGIC (talimogene laherparepvec): Amgen

• PROVENGE (sipuleucel-T): Dendreon Pharmaceuticals

• IO102-IO103: IO Biotech

• CAN-2409: Candel Therapeutics

• mRNA-4157 (V940) + KEYTRUDA: Merck/Moderna

• GNOS-PV02: Geneos Therapeutics

• EO2401: Enterome

• VAC85135: Johnson & Johnson

Neoantigen Based Personalized Cancer Therapeutic Vaccines Route of Administration

Neoantigen Based Personalized Cancer Therapeutic Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Neoantigen Based Personalized Cancer Therapeutic Vaccines Molecule Type

Neoantigen Based Personalized Cancer Therapeutic Vaccines Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Therapeutics Assessment

• Neoantigen Based Personalized Cancer Therapeutic Vaccines Assessment by Product Type

• Neoantigen Based Personalized Cancer Therapeutic Vaccines By Stage and Product Type

• Neoantigen Based Personalized Cancer Therapeutic Vaccines Assessment by Route of Administration

• Neoantigen Based Personalized Cancer Therapeutic Vaccines By Stage and Route of Administration

• Neoantigen Based Personalized Cancer Therapeutic Vaccines Assessment by Molecule Type

• Neoantigen Based Personalized Cancer Therapeutic Vaccines by Stage and Molecule Type

DelveInsight’s Neoantigen Based Personalized Cancer Therapeutic Vaccines Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Neoantigen Based Personalized Cancer Therapeutic Vaccines product details are provided in the report. Download the Neoantigen Based Personalized Cancer Therapeutic Vaccines pipeline report to learn more about the emerging Neoantigen Based Personalized Cancer Therapeutic Vaccines therapies

Some of the key companies in the Neoantigen Based Personalized Cancer Therapeutic Vaccines Therapeutics Market include:

Key companies developing therapies for Neoantigen Based Personalized Cancer Therapeutic Vaccines are – BioNTech, Genentech, Moderna, Merck & Co., Gritstone bio, Evaxion Biotech, and others.

Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Analysis:

The Neoantigen Based Personalized Cancer Therapeutic Vaccines pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Neoantigen Based Personalized Cancer Therapeutic Vaccines with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neoantigen Based Personalized Cancer Therapeutic Vaccines Treatment

• Neoantigen Based Personalized Cancer Therapeutic Vaccines key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Neoantigen Based Personalized Cancer Therapeutic Vaccines Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neoantigen Based Personalized Cancer Therapeutic Vaccines market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neoantigen Based Personalized Cancer Therapeutic Vaccines drugs and therapies

Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Market Drivers

• Advancements in Genomic Sequencing, Growing Demand for Personalized Medicine, Rising Cancer Incidence, Increased Research & Development Funding, Combination Therapies with Immunotherapies, Regulatory Support & Fast-Track Approvals, are some of the important factors that are fueling the Neoantigen Based Personalized Cancer Therapeutic Vaccines Market.

Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Market Barriers

• However, High Development Costs, Complex Manufacturing Process, Regulatory & Approval Hurdles, Limited Clinical Data, Patient-Specific Variability, Infrastructure & Accessibility Issues, and other factors are creating obstacles in the Neoantigen Based Personalized Cancer Therapeutic Vaccines Market growth.

Scope of Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Drug Insight

• Coverage: Global

• Key Neoantigen Based Personalized Cancer Therapeutic Vaccines Companies: Evaxion Biotech, Nouscom, Amgen, Dendreon Pharmaceuticals, IO Biotech, Candel Therapeutics, Merck/Moderna, Geneos Therapeutics, Enterome, Johnson & Johnson, and others

• Key Neoantigen Based Personalized Cancer Therapeutic Vaccines Therapies: EVX-01, NOUS-PEV, IMLYGIC (talimogene laherparepvec), PROVENGE (sipuleucel-T), IO102-IO103, CAN-2409, mRNA-4157 (V940) + KEYTRUDA, GNOS-PV02, EO2401, VAC85135, and others

• Neoantigen Based Personalized Cancer Therapeutic Vaccines Therapeutic Assessment: Neoantigen Based Personalized Cancer Therapeutic Vaccines current marketed and Neoantigen Based Personalized Cancer Therapeutic Vaccines emerging therapies

• Neoantigen Based Personalized Cancer Therapeutic Vaccines Market Dynamics: Neoantigen Based Personalized Cancer Therapeutic Vaccines market drivers and Neoantigen Based Personalized Cancer Therapeutic Vaccines market barriers

Request for Sample PDF Report for Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Assessment and clinical trials

Table of Contents

1. Neoantigen Based Personalized Cancer Therapeutic Vaccines Report Introduction

2. Neoantigen Based Personalized Cancer Therapeutic Vaccines Executive Summary

3. Neoantigen Based Personalized Cancer Therapeutic Vaccines Overview

4. Neoantigen Based Personalized Cancer Therapeutic Vaccines- Analytical Perspective In-depth Commercial Assessment

5. Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Therapeutics

6. Neoantigen Based Personalized Cancer Therapeutic Vaccines Late Stage Products (Phase II/III)

7. Neoantigen Based Personalized Cancer Therapeutic Vaccines Mid Stage Products (Phase II)

8. Neoantigen Based Personalized Cancer Therapeutic Vaccines Early Stage Products (Phase I)

9. Neoantigen Based Personalized Cancer Therapeutic Vaccines Preclinical Stage Products

10. Neoantigen Based Personalized Cancer Therapeutic Vaccines Therapeutics Assessment

11. Neoantigen Based Personalized Cancer Therapeutic Vaccines Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neoantigen Based Personalized Cancer Therapeutic Vaccines Key Companies

14. Neoantigen Based Personalized Cancer Therapeutic Vaccines Key Products

15. Neoantigen Based Personalized Cancer Therapeutic Vaccines Unmet Needs

16 . Neoantigen Based Personalized Cancer Therapeutic Vaccines Market Drivers and Barriers

17. Neoantigen Based Personalized Cancer Therapeutic Vaccines Future Perspectives and Conclusion

18. Neoantigen Based Personalized Cancer Therapeutic Vaccines Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/